#ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

Gilead CEO Dan O’Day has been on a shop­ping spree. And while some an­a­lysts gawked at the biotech’s re­cent $21 bil­lion Im­munomedics buy­out, new da­ta re­leased at vir­tu­al ES­MO 2020 sug­gest the ac­qui­si­tion may have been worth the hefty price.

The deal, an­nounced last week­end, will give Cal­i­for­nia-based Gilead $GILD Trodelvy, which was re­cent­ly ap­proved for metasta­t­ic triple-neg­a­tive breast can­cer (mTNBC).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER